Galantamine

Drug Profile

Galantamine

Alternative Names: Galantamine Hydrobromide; Galanthamine; GP 37267; Nivalin; R 113675; Razadyne; Razadyne ER; Reminyl; Reminyl ER

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanochemia Pharmazeutika
  • Developer Janssen Pharmaceutical KK; Janssen-Cilag; Sanochemia Pharmazeutika
  • Class Alkaloids; Benzazepines; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase I/II Down syndrome
  • Discontinued Chronic fatigue syndrome; Delirium; Fibromyalgia; Mild cognitive impairment; Vascular dementia

Most Recent Events

  • 17 Dec 2016 Janssen-Cilag discontinues phase I/II trial in Down-syndrome (In children, In adolescents) in Belgium and Netherlands (EudraCT2006-003359-19) before December 2016
  • 15 Mar 2016 Biomarkers information updated
  • 05 Dec 2012 Efficacy data from a phase III trial in Alzheimer's disease released by Janssen Research and Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top